Traws Pharma, Inc. (NASDAQ:TRAW) Short Interest Update

Traws Pharma, Inc. (NASDAQ:TRAW) was the target of a large drop in short interest in the month of November. As of November 30th, there was short interest totalling 7,700 shares, a drop of 26.0% from the November 15th total of 10,400 shares. Based on an average daily volume of 11,600 shares, the days-to-cover ratio is currently 0.7 days. Currently, 0.3% of the company’s shares are sold short.

Traws Pharma Trading Down 3.9 %

Shares of TRAW traded down $0.19 during midday trading on Friday, hitting $4.65. The stock had a trading volume of 4,442 shares, compared to its average volume of 5,948. The stock’s 50-day moving average price is $4.94. The company has a market capitalization of $14.09 million, a price-to-earnings ratio of -0.03 and a beta of 1.46. Traws Pharma has a fifty-two week low of $4.06 and a fifty-two week high of $27.50.

Traws Pharma Company Profile

Traws Pharma, Inc, a clinical stage biopharmaceutical company, focuses on developing small molecule oral product candidates for respiratory viral diseases and cancer. The company is developing investigational novel therapies for influenza and COVID19 that are designed to address treatment resistance, such as TRX01 (travatrelvir), a Mpro/3CL inhibitor in development for the treatment of COVID19; and TRX100 (viroxavir), an endonuclease inhibitor in development for the treatment of pandemic influenza.